nodes	percent_of_prediction	percent_of_DWPC	metapath
Memantine—CYP2A6—Methoxsalen—psoriasis	0.158	0.317	CbGbCtD
Memantine—CYP2A6—Prednisolone—psoriasis	0.0767	0.154	CbGbCtD
Memantine—CYP2B6—Cholecalciferol—psoriasis	0.0681	0.137	CbGbCtD
Memantine—CYP2A6—Dexamethasone—psoriasis	0.0452	0.0909	CbGbCtD
Memantine—CYP2C19—Cholecalciferol—psoriasis	0.0433	0.0869	CbGbCtD
Memantine—CYP2C19—Prednisone—psoriasis	0.03	0.0602	CbGbCtD
Memantine—CYP2B6—Dexamethasone—psoriasis	0.0295	0.0592	CbGbCtD
Memantine—CYP2C19—Cyclosporine—psoriasis	0.0284	0.0571	CbGbCtD
Memantine—CYP2C19—Dexamethasone—psoriasis	0.0187	0.0376	CbGbCtD
Memantine—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00189	0.0895	CbGpPWpGaD
Memantine—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00152	0.0722	CbGpPWpGaD
Memantine—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00117	0.0555	CbGpPWpGaD
Memantine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00115	0.0546	CbGpPWpGaD
Memantine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.000943	0.0448	CbGpPWpGaD
Memantine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000713	0.0338	CbGpPWpGaD
Memantine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000485	0.023	CbGpPWpGaD
Memantine—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000479	0.0227	CbGpPWpGaD
Memantine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000394	0.0187	CbGpPWpGaD
Memantine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000392	0.0186	CbGpPWpGaD
Memantine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000387	0.0183	CbGpPWpGaD
Memantine—HTR3A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000327	0.0155	CbGpPWpGaD
Memantine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000318	0.0151	CbGpPWpGaD
Memantine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000304	0.0144	CbGpPWpGaD
Memantine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000296	0.014	CbGpPWpGaD
Memantine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000292	0.0139	CbGpPWpGaD
Memantine—GRIN1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000272	0.0129	CbGpPWpGaD
Memantine—HTR3A—SIDS Susceptibility Pathways—IL13—psoriasis	0.000258	0.0122	CbGpPWpGaD
Memantine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00024	0.0114	CbGpPWpGaD
Memantine—GRIN2A—Alzheimers Disease—APOE—psoriasis	0.000218	0.0104	CbGpPWpGaD
Memantine—GRIN1—SIDS Susceptibility Pathways—IL13—psoriasis	0.000215	0.0102	CbGpPWpGaD
Memantine—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000209	0.00992	CbGpPWpGaD
Memantine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000202	0.00956	CbGpPWpGaD
Memantine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000194	0.00921	CbGpPWpGaD
Memantine—GRIN1—Alzheimers Disease—APOE—psoriasis	0.000191	0.00904	CbGpPWpGaD
Memantine—GRIN2B—Alzheimers Disease—APOE—psoriasis	0.000186	0.00881	CbGpPWpGaD
Memantine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000184	0.00875	CbGpPWpGaD
Memantine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00018	0.00854	CbGpPWpGaD
Memantine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000176	0.00836	CbGpPWpGaD
Memantine—DRD2—G alpha (i) signalling events—HCAR2—psoriasis	0.000173	0.00822	CbGpPWpGaD
Memantine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000169	0.00801	CbGpPWpGaD
Memantine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000166	0.0079	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—IL4—psoriasis	0.000163	0.00776	CbGpPWpGaD
Memantine—HTR3A—SIDS Susceptibility Pathways—IL10—psoriasis	0.000161	0.00766	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—LEP—psoriasis	0.000138	0.00656	CbGpPWpGaD
Memantine—DRD2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000138	0.00653	CbGpPWpGaD
Memantine—GRIN1—SIDS Susceptibility Pathways—IL10—psoriasis	0.000134	0.00638	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—ICAM1—psoriasis	0.00013	0.00616	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—NOS2—psoriasis	0.000129	0.00611	CbGpPWpGaD
Memantine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000127	0.00605	CbGpPWpGaD
Memantine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000126	0.00597	CbGpPWpGaD
Memantine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000125	0.00595	CbGpPWpGaD
Memantine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000124	0.00587	CbGpPWpGaD
Memantine—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000116	0.00552	CbGpPWpGaD
Memantine—GRIN1—BDNF signaling pathway—NFKBIA—psoriasis	0.00011	0.00521	CbGpPWpGaD
Memantine—GRIN2B—BDNF signaling pathway—NFKBIA—psoriasis	0.000107	0.00508	CbGpPWpGaD
Memantine—DRD2—GPCR ligand binding—HCAR2—psoriasis	0.000105	0.00498	CbGpPWpGaD
Memantine—GRIN2A—Alzheimers Disease—TNF—psoriasis	0.000101	0.0048	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—IFNG—psoriasis	9.88e-05	0.00469	CbGpPWpGaD
Memantine—HTR3A—Transmembrane transport of small molecules—CP—psoriasis	9.84e-05	0.00467	CbGpPWpGaD
Memantine—HTR3A—Transmembrane transport of small molecules—CARM1—psoriasis	9.39e-05	0.00446	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—CARM1—psoriasis	9.2e-05	0.00437	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—CXCL8—psoriasis	9.18e-05	0.00436	CbGpPWpGaD
Memantine—DRD2—G alpha (i) signalling events—CCL20—psoriasis	8.99e-05	0.00427	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—CARM1—psoriasis	8.97e-05	0.00426	CbGpPWpGaD
Memantine—GRIN1—EPH-Ephrin signaling—VEGFA—psoriasis	8.95e-05	0.00425	CbGpPWpGaD
Memantine—GRIN2A—Alzheimers Disease—TP53—psoriasis	8.91e-05	0.00423	CbGpPWpGaD
Memantine—HTR3A—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.83e-05	0.00419	CbGpPWpGaD
Memantine—GRIN1—Alzheimers Disease—TNF—psoriasis	8.81e-05	0.00418	CbGpPWpGaD
Memantine—GRIN2B—EPH-Ephrin signaling—VEGFA—psoriasis	8.72e-05	0.00414	CbGpPWpGaD
Memantine—GRIN2B—Alzheimers Disease—TNF—psoriasis	8.59e-05	0.00408	CbGpPWpGaD
Memantine—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	8.38e-05	0.00398	CbGpPWpGaD
Memantine—HTR3A—SIDS Susceptibility Pathways—JUN—psoriasis	8.21e-05	0.0039	CbGpPWpGaD
Memantine—Anxiety—Betamethasone—psoriasis	8.13e-05	0.000169	CcSEcCtD
Memantine—Vomiting—Mycophenolic acid—psoriasis	8.1e-05	0.000168	CcSEcCtD
Memantine—Discomfort—Dexamethasone—psoriasis	8.06e-05	0.000168	CcSEcCtD
Memantine—Discomfort—Betamethasone—psoriasis	8.06e-05	0.000168	CcSEcCtD
Memantine—Dyspepsia—Hydrocortisone—psoriasis	8.06e-05	0.000167	CcSEcCtD
Memantine—Haemoglobin—Methotrexate—psoriasis	8.05e-05	0.000167	CcSEcCtD
Memantine—Rash—Mycophenolic acid—psoriasis	8.03e-05	0.000167	CcSEcCtD
Memantine—Dermatitis—Mycophenolic acid—psoriasis	8.02e-05	0.000167	CcSEcCtD
Memantine—Pain—Prednisolone—psoriasis	8.02e-05	0.000167	CcSEcCtD
Memantine—Haemorrhage—Methotrexate—psoriasis	8.01e-05	0.000167	CcSEcCtD
Memantine—Hepatitis—Methotrexate—psoriasis	8.01e-05	0.000167	CcSEcCtD
Memantine—Urticaria—Mycophenolate mofetil—psoriasis	7.98e-05	0.000166	CcSEcCtD
Memantine—Headache—Mycophenolic acid—psoriasis	7.98e-05	0.000166	CcSEcCtD
Memantine—Decreased appetite—Hydrocortisone—psoriasis	7.96e-05	0.000165	CcSEcCtD
Memantine—Pharyngitis—Methotrexate—psoriasis	7.95e-05	0.000165	CcSEcCtD
Memantine—Abdominal pain—Mycophenolate mofetil—psoriasis	7.94e-05	0.000165	CcSEcCtD
Memantine—Body temperature increased—Mycophenolate mofetil—psoriasis	7.94e-05	0.000165	CcSEcCtD
Memantine—Urinary tract disorder—Methotrexate—psoriasis	7.91e-05	0.000164	CcSEcCtD
Memantine—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.9e-05	0.000164	CcSEcCtD
Memantine—HTR3A—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.9e-05	0.00375	CbGpPWpGaD
Memantine—Fatigue—Hydrocortisone—psoriasis	7.89e-05	0.000164	CcSEcCtD
Memantine—Vision blurred—Prednisone—psoriasis	7.87e-05	0.000163	CcSEcCtD
Memantine—Urethral disorder—Methotrexate—psoriasis	7.85e-05	0.000163	CcSEcCtD
Memantine—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.85e-05	0.000163	CcSEcCtD
Memantine—Pain—Hydrocortisone—psoriasis	7.83e-05	0.000163	CcSEcCtD
Memantine—Oedema—Dexamethasone—psoriasis	7.82e-05	0.000163	CcSEcCtD
Memantine—Oedema—Betamethasone—psoriasis	7.82e-05	0.000163	CcSEcCtD
Memantine—Insomnia—Triamcinolone—psoriasis	7.8e-05	0.000162	CcSEcCtD
Memantine—Infection—Betamethasone—psoriasis	7.77e-05	0.000161	CcSEcCtD
Memantine—Infection—Dexamethasone—psoriasis	7.77e-05	0.000161	CcSEcCtD
Memantine—GRIN1—Alzheimers Disease—TP53—psoriasis	7.77e-05	0.00369	CbGpPWpGaD
Memantine—Ill-defined disorder—Prednisone—psoriasis	7.74e-05	0.000161	CcSEcCtD
Memantine—Paraesthesia—Triamcinolone—psoriasis	7.74e-05	0.000161	CcSEcCtD
Memantine—Feeling abnormal—Prednisolone—psoriasis	7.72e-05	0.000161	CcSEcCtD
Memantine—Visual impairment—Methotrexate—psoriasis	7.72e-05	0.00016	CcSEcCtD
Memantine—Anaemia—Prednisone—psoriasis	7.71e-05	0.00016	CcSEcCtD
Memantine—Shock—Betamethasone—psoriasis	7.69e-05	0.00016	CcSEcCtD
Memantine—Shock—Dexamethasone—psoriasis	7.69e-05	0.00016	CcSEcCtD
Memantine—Dyspnoea—Triamcinolone—psoriasis	7.68e-05	0.00016	CcSEcCtD
Memantine—Nervous system disorder—Betamethasone—psoriasis	7.67e-05	0.000159	CcSEcCtD
Memantine—Nervous system disorder—Dexamethasone—psoriasis	7.67e-05	0.000159	CcSEcCtD
Memantine—Agitation—Prednisone—psoriasis	7.67e-05	0.000159	CcSEcCtD
Memantine—Thrombocytopenia—Dexamethasone—psoriasis	7.66e-05	0.000159	CcSEcCtD
Memantine—Thrombocytopenia—Betamethasone—psoriasis	7.66e-05	0.000159	CcSEcCtD
Memantine—Tachycardia—Dexamethasone—psoriasis	7.63e-05	0.000159	CcSEcCtD
Memantine—Tachycardia—Betamethasone—psoriasis	7.63e-05	0.000159	CcSEcCtD
Memantine—Hypersensitivity—Cyclosporine—psoriasis	7.59e-05	0.000158	CcSEcCtD
Memantine—Dyspepsia—Triamcinolone—psoriasis	7.59e-05	0.000158	CcSEcCtD
Memantine—Erythema multiforme—Methotrexate—psoriasis	7.58e-05	0.000157	CcSEcCtD
Memantine—GRIN2B—Alzheimers Disease—TP53—psoriasis	7.57e-05	0.00359	CbGpPWpGaD
Memantine—Nausea—Mycophenolic acid—psoriasis	7.56e-05	0.000157	CcSEcCtD
Memantine—Hyperhidrosis—Betamethasone—psoriasis	7.56e-05	0.000157	CcSEcCtD
Memantine—Hyperhidrosis—Dexamethasone—psoriasis	7.56e-05	0.000157	CcSEcCtD
Memantine—Feeling abnormal—Hydrocortisone—psoriasis	7.54e-05	0.000157	CcSEcCtD
Memantine—Malaise—Prednisone—psoriasis	7.53e-05	0.000156	CcSEcCtD
Memantine—Vertigo—Prednisone—psoriasis	7.5e-05	0.000156	CcSEcCtD
Memantine—Eye disorder—Methotrexate—psoriasis	7.49e-05	0.000156	CcSEcCtD
Memantine—Gastrointestinal pain—Hydrocortisone—psoriasis	7.49e-05	0.000156	CcSEcCtD
Memantine—Syncope—Prednisone—psoriasis	7.48e-05	0.000156	CcSEcCtD
Memantine—Tinnitus—Methotrexate—psoriasis	7.47e-05	0.000155	CcSEcCtD
Memantine—Anorexia—Betamethasone—psoriasis	7.46e-05	0.000155	CcSEcCtD
Memantine—Anorexia—Dexamethasone—psoriasis	7.46e-05	0.000155	CcSEcCtD
Memantine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	7.45e-05	0.00354	CbGpPWpGaD
Memantine—Urticaria—Prednisolone—psoriasis	7.45e-05	0.000155	CcSEcCtD
Memantine—Cardiac disorder—Methotrexate—psoriasis	7.44e-05	0.000155	CcSEcCtD
Memantine—Fatigue—Triamcinolone—psoriasis	7.43e-05	0.000154	CcSEcCtD
Memantine—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.4e-05	0.000154	CcSEcCtD
Memantine—Asthenia—Cyclosporine—psoriasis	7.39e-05	0.000154	CcSEcCtD
Memantine—Pain—Triamcinolone—psoriasis	7.37e-05	0.000153	CcSEcCtD
Memantine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7.35e-05	0.00349	CbGpPWpGaD
Memantine—GRIN1—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.35e-05	0.00349	CbGpPWpGaD
Memantine—Loss of consciousness—Prednisone—psoriasis	7.34e-05	0.000152	CcSEcCtD
Memantine—Hypotension—Dexamethasone—psoriasis	7.31e-05	0.000152	CcSEcCtD
Memantine—Hypotension—Betamethasone—psoriasis	7.31e-05	0.000152	CcSEcCtD
Memantine—Pruritus—Cyclosporine—psoriasis	7.29e-05	0.000151	CcSEcCtD
Memantine—GRIN1—BDNF signaling pathway—JUN—psoriasis	7.28e-05	0.00346	CbGpPWpGaD
Memantine—Urticaria—Hydrocortisone—psoriasis	7.27e-05	0.000151	CcSEcCtD
Memantine—Angiopathy—Methotrexate—psoriasis	7.27e-05	0.000151	CcSEcCtD
Memantine—Immune system disorder—Methotrexate—psoriasis	7.24e-05	0.00015	CcSEcCtD
Memantine—Body temperature increased—Hydrocortisone—psoriasis	7.24e-05	0.00015	CcSEcCtD
Memantine—Abdominal pain—Hydrocortisone—psoriasis	7.24e-05	0.00015	CcSEcCtD
Memantine—Convulsion—Prednisone—psoriasis	7.23e-05	0.00015	CcSEcCtD
Memantine—Mediastinal disorder—Methotrexate—psoriasis	7.22e-05	0.00015	CcSEcCtD
Memantine—Asthenia—Mycophenolate mofetil—psoriasis	7.21e-05	0.00015	CcSEcCtD
Memantine—Hypertension—Prednisone—psoriasis	7.21e-05	0.00015	CcSEcCtD
Memantine—Chills—Methotrexate—psoriasis	7.19e-05	0.000149	CcSEcCtD
Memantine—HTR3A—SIDS Susceptibility Pathways—VEGFA—psoriasis	7.17e-05	0.0034	CbGpPWpGaD
Memantine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.15e-05	0.00339	CbGpPWpGaD
Memantine—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.13e-05	0.000148	CcSEcCtD
Memantine—Musculoskeletal discomfort—Betamethasone—psoriasis	7.13e-05	0.000148	CcSEcCtD
Memantine—Pruritus—Mycophenolate mofetil—psoriasis	7.11e-05	0.000148	CcSEcCtD
Memantine—Arthralgia—Prednisone—psoriasis	7.11e-05	0.000148	CcSEcCtD
Memantine—Myalgia—Prednisone—psoriasis	7.11e-05	0.000148	CcSEcCtD
Memantine—Feeling abnormal—Triamcinolone—psoriasis	7.1e-05	0.000148	CcSEcCtD
Memantine—GRIN2B—BDNF signaling pathway—JUN—psoriasis	7.1e-05	0.00337	CbGpPWpGaD
Memantine—Anxiety—Prednisone—psoriasis	7.08e-05	0.000147	CcSEcCtD
Memantine—Alopecia—Methotrexate—psoriasis	7.08e-05	0.000147	CcSEcCtD
Memantine—Insomnia—Betamethasone—psoriasis	7.07e-05	0.000147	CcSEcCtD
Memantine—Insomnia—Dexamethasone—psoriasis	7.07e-05	0.000147	CcSEcCtD
Memantine—Diarrhoea—Cyclosporine—psoriasis	7.05e-05	0.000146	CcSEcCtD
Memantine—Paraesthesia—Dexamethasone—psoriasis	7.02e-05	0.000146	CcSEcCtD
Memantine—Paraesthesia—Betamethasone—psoriasis	7.02e-05	0.000146	CcSEcCtD
Memantine—Discomfort—Prednisone—psoriasis	7.02e-05	0.000146	CcSEcCtD
Memantine—Mental disorder—Methotrexate—psoriasis	7.02e-05	0.000146	CcSEcCtD
Memantine—GRIN1—BDNF signaling pathway—NFKB1—psoriasis	7.01e-05	0.00333	CbGpPWpGaD
Memantine—Malnutrition—Methotrexate—psoriasis	6.97e-05	0.000145	CcSEcCtD
Memantine—Hypersensitivity—Prednisolone—psoriasis	6.91e-05	0.000144	CcSEcCtD
Memantine—Dyspepsia—Betamethasone—psoriasis	6.88e-05	0.000143	CcSEcCtD
Memantine—Dyspepsia—Dexamethasone—psoriasis	6.88e-05	0.000143	CcSEcCtD
Memantine—Diarrhoea—Mycophenolate mofetil—psoriasis	6.88e-05	0.000143	CcSEcCtD
Memantine—Urticaria—Triamcinolone—psoriasis	6.85e-05	0.000142	CcSEcCtD
Memantine—GRIN2B—BDNF signaling pathway—NFKB1—psoriasis	6.83e-05	0.00324	CbGpPWpGaD
Memantine—Dysgeusia—Methotrexate—psoriasis	6.83e-05	0.000142	CcSEcCtD
Memantine—GRIN1—SIDS Susceptibility Pathways—JUN—psoriasis	6.83e-05	0.00324	CbGpPWpGaD
Memantine—Body temperature increased—Triamcinolone—psoriasis	6.81e-05	0.000142	CcSEcCtD
Memantine—Dizziness—Cyclosporine—psoriasis	6.81e-05	0.000142	CcSEcCtD
Memantine—Oedema—Prednisone—psoriasis	6.81e-05	0.000142	CcSEcCtD
Memantine—Decreased appetite—Dexamethasone—psoriasis	6.8e-05	0.000141	CcSEcCtD
Memantine—Decreased appetite—Betamethasone—psoriasis	6.8e-05	0.000141	CcSEcCtD
Memantine—Infection—Prednisone—psoriasis	6.77e-05	0.000141	CcSEcCtD
Memantine—Gastrointestinal disorder—Betamethasone—psoriasis	6.75e-05	0.00014	CcSEcCtD
Memantine—Gastrointestinal disorder—Dexamethasone—psoriasis	6.75e-05	0.00014	CcSEcCtD
Memantine—Back pain—Methotrexate—psoriasis	6.75e-05	0.00014	CcSEcCtD
Memantine—Hypersensitivity—Hydrocortisone—psoriasis	6.74e-05	0.00014	CcSEcCtD
Memantine—Fatigue—Dexamethasone—psoriasis	6.74e-05	0.00014	CcSEcCtD
Memantine—Fatigue—Betamethasone—psoriasis	6.74e-05	0.00014	CcSEcCtD
Memantine—Shock—Prednisone—psoriasis	6.7e-05	0.000139	CcSEcCtD
Memantine—Pain—Dexamethasone—psoriasis	6.69e-05	0.000139	CcSEcCtD
Memantine—Pain—Betamethasone—psoriasis	6.69e-05	0.000139	CcSEcCtD
Memantine—Nervous system disorder—Prednisone—psoriasis	6.68e-05	0.000139	CcSEcCtD
Memantine—Tachycardia—Prednisone—psoriasis	6.65e-05	0.000138	CcSEcCtD
Memantine—Dizziness—Mycophenolate mofetil—psoriasis	6.64e-05	0.000138	CcSEcCtD
Memantine—Skin disorder—Prednisone—psoriasis	6.62e-05	0.000137	CcSEcCtD
Memantine—Hyperhidrosis—Prednisone—psoriasis	6.58e-05	0.000137	CcSEcCtD
Memantine—GRIN1—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.57e-05	0.00312	CbGpPWpGaD
Memantine—Vision blurred—Methotrexate—psoriasis	6.57e-05	0.000137	CcSEcCtD
Memantine—Asthenia—Hydrocortisone—psoriasis	6.57e-05	0.000136	CcSEcCtD
Memantine—Vomiting—Cyclosporine—psoriasis	6.55e-05	0.000136	CcSEcCtD
Memantine—Rash—Cyclosporine—psoriasis	6.49e-05	0.000135	CcSEcCtD
Memantine—Anorexia—Prednisone—psoriasis	6.49e-05	0.000135	CcSEcCtD
Memantine—Dermatitis—Cyclosporine—psoriasis	6.49e-05	0.000135	CcSEcCtD
Memantine—Pruritus—Hydrocortisone—psoriasis	6.48e-05	0.000135	CcSEcCtD
Memantine—Ill-defined disorder—Methotrexate—psoriasis	6.47e-05	0.000134	CcSEcCtD
Memantine—Headache—Cyclosporine—psoriasis	6.45e-05	0.000134	CcSEcCtD
Memantine—Anaemia—Methotrexate—psoriasis	6.45e-05	0.000134	CcSEcCtD
Memantine—Feeling abnormal—Dexamethasone—psoriasis	6.44e-05	0.000134	CcSEcCtD
Memantine—Feeling abnormal—Betamethasone—psoriasis	6.44e-05	0.000134	CcSEcCtD
Memantine—Gastrointestinal pain—Betamethasone—psoriasis	6.4e-05	0.000133	CcSEcCtD
Memantine—Gastrointestinal pain—Dexamethasone—psoriasis	6.4e-05	0.000133	CcSEcCtD
Memantine—GRIN1—Spinal Cord Injury—TNF—psoriasis	6.39e-05	0.00303	CbGpPWpGaD
Memantine—Vomiting—Mycophenolate mofetil—psoriasis	6.39e-05	0.000133	CcSEcCtD
Memantine—Hypersensitivity—Triamcinolone—psoriasis	6.35e-05	0.000132	CcSEcCtD
Memantine—Rash—Mycophenolate mofetil—psoriasis	6.34e-05	0.000132	CcSEcCtD
Memantine—Dermatitis—Mycophenolate mofetil—psoriasis	6.33e-05	0.000132	CcSEcCtD
Memantine—GRIN1—BDNF signaling pathway—STAT3—psoriasis	6.3e-05	0.00299	CbGpPWpGaD
Memantine—Headache—Mycophenolate mofetil—psoriasis	6.29e-05	0.000131	CcSEcCtD
Memantine—Malaise—Methotrexate—psoriasis	6.29e-05	0.000131	CcSEcCtD
Memantine—Vertigo—Methotrexate—psoriasis	6.27e-05	0.00013	CcSEcCtD
Memantine—Diarrhoea—Hydrocortisone—psoriasis	6.26e-05	0.00013	CcSEcCtD
Memantine—Leukopenia—Methotrexate—psoriasis	6.24e-05	0.00013	CcSEcCtD
Memantine—Urticaria—Dexamethasone—psoriasis	6.21e-05	0.000129	CcSEcCtD
Memantine—Urticaria—Betamethasone—psoriasis	6.21e-05	0.000129	CcSEcCtD
Memantine—Musculoskeletal discomfort—Prednisone—psoriasis	6.21e-05	0.000129	CcSEcCtD
Memantine—Dizziness—Prednisolone—psoriasis	6.2e-05	0.000129	CcSEcCtD
Memantine—Asthenia—Triamcinolone—psoriasis	6.18e-05	0.000129	CcSEcCtD
Memantine—Abdominal pain—Betamethasone—psoriasis	6.18e-05	0.000128	CcSEcCtD
Memantine—Body temperature increased—Dexamethasone—psoriasis	6.18e-05	0.000128	CcSEcCtD
Memantine—Abdominal pain—Dexamethasone—psoriasis	6.18e-05	0.000128	CcSEcCtD
Memantine—Body temperature increased—Betamethasone—psoriasis	6.18e-05	0.000128	CcSEcCtD
Memantine—Insomnia—Prednisone—psoriasis	6.16e-05	0.000128	CcSEcCtD
Memantine—HTR3A—SIDS Susceptibility Pathways—TNF—psoriasis	6.14e-05	0.00292	CbGpPWpGaD
Memantine—GRIN2B—BDNF signaling pathway—STAT3—psoriasis	6.14e-05	0.00291	CbGpPWpGaD
Memantine—Nausea—Cyclosporine—psoriasis	6.12e-05	0.000127	CcSEcCtD
Memantine—Paraesthesia—Prednisone—psoriasis	6.12e-05	0.000127	CcSEcCtD
Memantine—Pruritus—Triamcinolone—psoriasis	6.1e-05	0.000127	CcSEcCtD
Memantine—Cough—Methotrexate—psoriasis	6.09e-05	0.000126	CcSEcCtD
Memantine—Dizziness—Hydrocortisone—psoriasis	6.05e-05	0.000126	CcSEcCtD
Memantine—Convulsion—Methotrexate—psoriasis	6.04e-05	0.000126	CcSEcCtD
Memantine—Dyspepsia—Prednisone—psoriasis	6e-05	0.000125	CcSEcCtD
Memantine—Nausea—Mycophenolate mofetil—psoriasis	5.97e-05	0.000124	CcSEcCtD
Memantine—GRIN1—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.97e-05	0.00283	CbGpPWpGaD
Memantine—Myalgia—Methotrexate—psoriasis	5.94e-05	0.000123	CcSEcCtD
Memantine—Chest pain—Methotrexate—psoriasis	5.94e-05	0.000123	CcSEcCtD
Memantine—Arthralgia—Methotrexate—psoriasis	5.94e-05	0.000123	CcSEcCtD
Memantine—DRD2—GPCR downstream signaling—HCAR2—psoriasis	5.92e-05	0.00281	CbGpPWpGaD
Memantine—Decreased appetite—Prednisone—psoriasis	5.92e-05	0.000123	CcSEcCtD
Memantine—Rash—Prednisolone—psoriasis	5.91e-05	0.000123	CcSEcCtD
Memantine—Dermatitis—Prednisolone—psoriasis	5.9e-05	0.000123	CcSEcCtD
Memantine—Fatigue—Prednisone—psoriasis	5.87e-05	0.000122	CcSEcCtD
Memantine—Headache—Prednisolone—psoriasis	5.87e-05	0.000122	CcSEcCtD
Memantine—Discomfort—Methotrexate—psoriasis	5.87e-05	0.000122	CcSEcCtD
Memantine—Constipation—Prednisone—psoriasis	5.82e-05	0.000121	CcSEcCtD
Memantine—Vomiting—Hydrocortisone—psoriasis	5.82e-05	0.000121	CcSEcCtD
Memantine—Rash—Hydrocortisone—psoriasis	5.77e-05	0.00012	CcSEcCtD
Memantine—Dermatitis—Hydrocortisone—psoriasis	5.77e-05	0.00012	CcSEcCtD
Memantine—Confusional state—Methotrexate—psoriasis	5.74e-05	0.000119	CcSEcCtD
Memantine—Headache—Hydrocortisone—psoriasis	5.73e-05	0.000119	CcSEcCtD
Memantine—Dizziness—Triamcinolone—psoriasis	5.7e-05	0.000118	CcSEcCtD
Memantine—Infection—Methotrexate—psoriasis	5.66e-05	0.000118	CcSEcCtD
Memantine—GRIN1—Spinal Cord Injury—TP53—psoriasis	5.64e-05	0.00267	CbGpPWpGaD
Memantine—Feeling abnormal—Prednisone—psoriasis	5.61e-05	0.000117	CcSEcCtD
Memantine—Asthenia—Dexamethasone—psoriasis	5.61e-05	0.000117	CcSEcCtD
Memantine—Asthenia—Betamethasone—psoriasis	5.61e-05	0.000117	CcSEcCtD
Memantine—Nervous system disorder—Methotrexate—psoriasis	5.58e-05	0.000116	CcSEcCtD
Memantine—Thrombocytopenia—Methotrexate—psoriasis	5.57e-05	0.000116	CcSEcCtD
Memantine—Gastrointestinal pain—Prednisone—psoriasis	5.57e-05	0.000116	CcSEcCtD
Memantine—Nausea—Prednisolone—psoriasis	5.57e-05	0.000116	CcSEcCtD
Memantine—Pruritus—Betamethasone—psoriasis	5.53e-05	0.000115	CcSEcCtD
Memantine—Pruritus—Dexamethasone—psoriasis	5.53e-05	0.000115	CcSEcCtD
Memantine—Skin disorder—Methotrexate—psoriasis	5.53e-05	0.000115	CcSEcCtD
Memantine—Hyperhidrosis—Methotrexate—psoriasis	5.5e-05	0.000114	CcSEcCtD
Memantine—Vomiting—Triamcinolone—psoriasis	5.48e-05	0.000114	CcSEcCtD
Memantine—DRD2—GPCR ligand binding—CCL20—psoriasis	5.44e-05	0.00258	CbGpPWpGaD
Memantine—Nausea—Hydrocortisone—psoriasis	5.44e-05	0.000113	CcSEcCtD
Memantine—Rash—Triamcinolone—psoriasis	5.43e-05	0.000113	CcSEcCtD
Memantine—Dermatitis—Triamcinolone—psoriasis	5.43e-05	0.000113	CcSEcCtD
Memantine—Anorexia—Methotrexate—psoriasis	5.43e-05	0.000113	CcSEcCtD
Memantine—Urticaria—Prednisone—psoriasis	5.41e-05	0.000112	CcSEcCtD
Memantine—Headache—Triamcinolone—psoriasis	5.4e-05	0.000112	CcSEcCtD
Memantine—Abdominal pain—Prednisone—psoriasis	5.38e-05	0.000112	CcSEcCtD
Memantine—Body temperature increased—Prednisone—psoriasis	5.38e-05	0.000112	CcSEcCtD
Memantine—DRD2—Signaling by GPCR—HCAR2—psoriasis	5.38e-05	0.00255	CbGpPWpGaD
Memantine—Diarrhoea—Dexamethasone—psoriasis	5.35e-05	0.000111	CcSEcCtD
Memantine—Diarrhoea—Betamethasone—psoriasis	5.35e-05	0.000111	CcSEcCtD
Memantine—Hypotension—Methotrexate—psoriasis	5.32e-05	0.000111	CcSEcCtD
Memantine—Musculoskeletal discomfort—Methotrexate—psoriasis	5.19e-05	0.000108	CcSEcCtD
Memantine—Dizziness—Betamethasone—psoriasis	5.17e-05	0.000107	CcSEcCtD
Memantine—Dizziness—Dexamethasone—psoriasis	5.17e-05	0.000107	CcSEcCtD
Memantine—GRIN1—Spinal Cord Injury—IL6—psoriasis	5.16e-05	0.00245	CbGpPWpGaD
Memantine—Insomnia—Methotrexate—psoriasis	5.15e-05	0.000107	CcSEcCtD
Memantine—Nausea—Triamcinolone—psoriasis	5.12e-05	0.000106	CcSEcCtD
Memantine—GRIN1—SIDS Susceptibility Pathways—TNF—psoriasis	5.11e-05	0.00243	CbGpPWpGaD
Memantine—Paraesthesia—Methotrexate—psoriasis	5.11e-05	0.000106	CcSEcCtD
Memantine—Dyspnoea—Methotrexate—psoriasis	5.07e-05	0.000105	CcSEcCtD
Memantine—Somnolence—Methotrexate—psoriasis	5.06e-05	0.000105	CcSEcCtD
Memantine—Hypersensitivity—Prednisone—psoriasis	5.02e-05	0.000104	CcSEcCtD
Memantine—Dyspepsia—Methotrexate—psoriasis	5.01e-05	0.000104	CcSEcCtD
Memantine—Vomiting—Betamethasone—psoriasis	4.97e-05	0.000103	CcSEcCtD
Memantine—Vomiting—Dexamethasone—psoriasis	4.97e-05	0.000103	CcSEcCtD
Memantine—HTR3A—SIDS Susceptibility Pathways—IL6—psoriasis	4.96e-05	0.00235	CbGpPWpGaD
Memantine—Decreased appetite—Methotrexate—psoriasis	4.95e-05	0.000103	CcSEcCtD
Memantine—Rash—Dexamethasone—psoriasis	4.93e-05	0.000102	CcSEcCtD
Memantine—Rash—Betamethasone—psoriasis	4.93e-05	0.000102	CcSEcCtD
Memantine—Dermatitis—Dexamethasone—psoriasis	4.93e-05	0.000102	CcSEcCtD
Memantine—Dermatitis—Betamethasone—psoriasis	4.93e-05	0.000102	CcSEcCtD
Memantine—Gastrointestinal disorder—Methotrexate—psoriasis	4.91e-05	0.000102	CcSEcCtD
Memantine—Fatigue—Methotrexate—psoriasis	4.91e-05	0.000102	CcSEcCtD
Memantine—Headache—Dexamethasone—psoriasis	4.9e-05	0.000102	CcSEcCtD
Memantine—Headache—Betamethasone—psoriasis	4.9e-05	0.000102	CcSEcCtD
Memantine—Asthenia—Prednisone—psoriasis	4.89e-05	0.000102	CcSEcCtD
Memantine—Pain—Methotrexate—psoriasis	4.87e-05	0.000101	CcSEcCtD
Memantine—Pruritus—Prednisone—psoriasis	4.82e-05	0.0001	CcSEcCtD
Memantine—GRIN1—Axon guidance—TYK2—psoriasis	4.7e-05	0.00223	CbGpPWpGaD
Memantine—Feeling abnormal—Methotrexate—psoriasis	4.69e-05	9.75e-05	CcSEcCtD
Memantine—Diarrhoea—Prednisone—psoriasis	4.66e-05	9.69e-05	CcSEcCtD
Memantine—Gastrointestinal pain—Methotrexate—psoriasis	4.65e-05	9.67e-05	CcSEcCtD
Memantine—Nausea—Betamethasone—psoriasis	4.65e-05	9.65e-05	CcSEcCtD
Memantine—Nausea—Dexamethasone—psoriasis	4.65e-05	9.65e-05	CcSEcCtD
Memantine—GRIN2B—Axon guidance—TYK2—psoriasis	4.58e-05	0.00218	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—NDUFA5—psoriasis	4.58e-05	0.00217	CbGpPWpGaD
Memantine—Urticaria—Methotrexate—psoriasis	4.52e-05	9.4e-05	CcSEcCtD
Memantine—Dizziness—Prednisone—psoriasis	4.5e-05	9.36e-05	CcSEcCtD
Memantine—Abdominal pain—Methotrexate—psoriasis	4.5e-05	9.35e-05	CcSEcCtD
Memantine—Body temperature increased—Methotrexate—psoriasis	4.5e-05	9.35e-05	CcSEcCtD
Memantine—GRIN1—Developmental Biology—LEP—psoriasis	4.4e-05	0.00209	CbGpPWpGaD
Memantine—Vomiting—Prednisone—psoriasis	4.33e-05	9e-05	CcSEcCtD
Memantine—Rash—Prednisone—psoriasis	4.29e-05	8.93e-05	CcSEcCtD
Memantine—Dermatitis—Prednisone—psoriasis	4.29e-05	8.92e-05	CcSEcCtD
Memantine—GRIN2B—Developmental Biology—LEP—psoriasis	4.29e-05	0.00203	CbGpPWpGaD
Memantine—Headache—Prednisone—psoriasis	4.27e-05	8.87e-05	CcSEcCtD
Memantine—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	4.26e-05	0.00202	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—NDUFA5—psoriasis	4.2e-05	0.002	CbGpPWpGaD
Memantine—Hypersensitivity—Methotrexate—psoriasis	4.19e-05	8.72e-05	CcSEcCtD
Memantine—DRD2—Circadian rythm related genes—LEP—psoriasis	4.14e-05	0.00197	CbGpPWpGaD
Memantine—GRIN1—SIDS Susceptibility Pathways—IL6—psoriasis	4.13e-05	0.00196	CbGpPWpGaD
Memantine—Asthenia—Methotrexate—psoriasis	4.08e-05	8.49e-05	CcSEcCtD
Memantine—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.06e-05	0.00193	CbGpPWpGaD
Memantine—Nausea—Prednisone—psoriasis	4.05e-05	8.41e-05	CcSEcCtD
Memantine—Pruritus—Methotrexate—psoriasis	4.03e-05	8.37e-05	CcSEcCtD
Memantine—Diarrhoea—Methotrexate—psoriasis	3.89e-05	8.09e-05	CcSEcCtD
Memantine—SLC22A2—Metabolism—CYP2S1—psoriasis	3.89e-05	0.00185	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—NOS2—psoriasis	3.86e-05	0.00183	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—PPARG—psoriasis	3.83e-05	0.00182	CbGpPWpGaD
Memantine—Dizziness—Methotrexate—psoriasis	3.76e-05	7.82e-05	CcSEcCtD
Memantine—GRIN2B—Developmental Biology—PPARG—psoriasis	3.73e-05	0.00177	CbGpPWpGaD
Memantine—Vomiting—Methotrexate—psoriasis	3.62e-05	7.52e-05	CcSEcCtD
Memantine—DRD2—Circadian rythm related genes—PPARG—psoriasis	3.61e-05	0.00171	CbGpPWpGaD
Memantine—Rash—Methotrexate—psoriasis	3.59e-05	7.46e-05	CcSEcCtD
Memantine—Dermatitis—Methotrexate—psoriasis	3.59e-05	7.45e-05	CcSEcCtD
Memantine—CYP2A6—Metabolism—CYP2S1—psoriasis	3.57e-05	0.0017	CbGpPWpGaD
Memantine—Headache—Methotrexate—psoriasis	3.57e-05	7.41e-05	CcSEcCtD
Memantine—CYP2B6—Metabolism—NDUFA5—psoriasis	3.39e-05	0.00161	CbGpPWpGaD
Memantine—Nausea—Methotrexate—psoriasis	3.38e-05	7.03e-05	CcSEcCtD
Memantine—GRIN1—Developmental Biology—TYK2—psoriasis	3.35e-05	0.00159	CbGpPWpGaD
Memantine—GRIN1—Axon guidance—VEGFA—psoriasis	3.32e-05	0.00158	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—TYK2—psoriasis	3.27e-05	0.00155	CbGpPWpGaD
Memantine—GRIN2B—Axon guidance—VEGFA—psoriasis	3.24e-05	0.00154	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—HCAR2—psoriasis	3.18e-05	0.00151	CbGpPWpGaD
Memantine—DRD2—GPCR downstream signaling—CCL20—psoriasis	3.08e-05	0.00146	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—CYP2S1—psoriasis	2.88e-05	0.00137	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—CCL20—psoriasis	2.79e-05	0.00133	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—TAGAP—psoriasis	2.76e-05	0.00131	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—NFKB1—psoriasis	2.61e-05	0.00124	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.56e-05	0.00122	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—JUN—psoriasis	2.56e-05	0.00121	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—NFKB1—psoriasis	2.55e-05	0.00121	CbGpPWpGaD
Memantine—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	2.43e-05	0.00115	CbGpPWpGaD
Memantine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.39e-05	0.00113	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—VEGFA—psoriasis	2.37e-05	0.00113	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—STAT3—psoriasis	2.35e-05	0.00111	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—VEGFA—psoriasis	2.31e-05	0.0011	CbGpPWpGaD
Memantine—GRIN1—Axon guidance—IL6—psoriasis	2.3e-05	0.00109	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—STAT3—psoriasis	2.29e-05	0.00109	CbGpPWpGaD
Memantine—GRIN2B—Axon guidance—IL6—psoriasis	2.24e-05	0.00106	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.18e-05	0.00103	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—TNF—psoriasis	2.03e-05	0.000965	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—TNF—psoriasis	1.98e-05	0.000941	CbGpPWpGaD
Memantine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.93e-05	0.000916	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—CARM1—psoriasis	1.9e-05	0.000903	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—CARM1—psoriasis	1.75e-05	0.000829	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—TP53—psoriasis	1.69e-05	0.000802	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—CCL20—psoriasis	1.65e-05	0.000783	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—IL6—psoriasis	1.64e-05	0.000779	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—IL6—psoriasis	1.6e-05	0.000759	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—IL6—psoriasis	1.55e-05	0.000734	CbGpPWpGaD
Memantine—DRD2—GPCR ligand binding—CXCL8—psoriasis	1.47e-05	0.000698	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—CARM1—psoriasis	1.41e-05	0.000669	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—CAT—psoriasis	1.17e-05	0.000555	CbGpPWpGaD
Memantine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.14e-05	0.000542	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—CAT—psoriasis	1.07e-05	0.00051	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—CARM1—psoriasis	1.06e-05	0.000505	CbGpPWpGaD
Memantine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.95e-06	0.000472	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—APOE—psoriasis	9.09e-06	0.000431	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—SOCS1—psoriasis	9.09e-06	0.000431	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—TYK2—psoriasis	8.67e-06	0.000411	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—CAT—psoriasis	8.66e-06	0.000411	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—APOE—psoriasis	8.34e-06	0.000396	CbGpPWpGaD
Memantine—DRD2—GPCR downstream signaling—CXCL8—psoriasis	8.31e-06	0.000394	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—PPARG—psoriasis	7.92e-06	0.000376	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—CXCL8—psoriasis	7.55e-06	0.000358	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—PPARG—psoriasis	7.27e-06	0.000345	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—APOE—psoriasis	6.73e-06	0.00032	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—LEP—psoriasis	6.71e-06	0.000318	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—APOE—psoriasis	6.71e-06	0.000318	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—CAT—psoriasis	6.55e-06	0.000311	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—NFKBIA—psoriasis	6.25e-06	0.000297	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—PPARG—psoriasis	5.86e-06	0.000278	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—TYK2—psoriasis	5.12e-06	0.000243	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—APOE—psoriasis	5.09e-06	0.000241	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—CXCL8—psoriasis	4.46e-06	0.000212	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—PPARG—psoriasis	4.43e-06	0.00021	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—IL6—psoriasis	4.24e-06	0.000201	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—JUN—psoriasis	4.14e-06	0.000197	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—NFKB1—psoriasis	3.99e-06	0.000189	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—VEGFA—psoriasis	3.62e-06	0.000172	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—STAT3—psoriasis	3.58e-06	0.00017	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—TP53—psoriasis	2.74e-06	0.00013	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—IL6—psoriasis	2.5e-06	0.000119	CbGpPWpGaD
